The Advanced Research and Diagnostic Laboratory (ARDL) is a Central Biochemistry Laboratory that provides the latest technology and clinical laboratory testing services to researchers and other customers via a 16,000-square-foot customized facility.
Constructed in 2013, the ARDL facility is recognized worldwide as a front-runner in innovative design and operational excellence.
High-Volume Immunoassay Testing Platforms
- Specimen collection / processing
- Specimen testing and analysis
- Quality control / assurance
- Specimen storage
Mass Spectrometer Center
- Sample analysis
- Quantitative proteomics
- Assay development
- Assay validation
- Long-term sample storage
- Cell cryopreservation
- DNA sample storage
- Power back-up protection
ARDL is fully accredited as a highly complex laboratory by
- the Clinical Laboratory Improvement Act (CLIA)
- the College of American Pathologists (CAP)
- the New York State Department of Health.
High standards such as these are considered a starting point for ARDL, and a basis for a level of quality unsurpassed in the industry.
ARDL's Mass Spectrometer Center Ramps Up
For more than three decades, scientists in the Advanced Research and Diagnostic Laboratory (ARDL) at the University of Minnesota have conducted large-scale analysis of biological specimens for NIH-sponsored multi-center clinical trials. The recent expansion of its Mass Spectrometer Center will enable ARDL to bring “gold standard” analysis more fully into its clinical testing operations and help investigators study renal, diabetes, nutritional, cardiovascular and other diagnostic biomarkers.
“Mass spectrometry is increasingly being integrated into clinical laboratories,” said center director Jesse Seegmiller. According to Seegmiller, most large clinical laboratories are now incorporating mass spectrometry systems in their testing repertoire.” Mass spectrometry can help “bridge a gap that has existed for clinical trials and various research studies by obtaining results from a mass spectrometry platform to perform analyses not possible using standard clinical analyzer systems.” One of the most impressive benefits of these systems is the analytical specificity advantages they provide. This has resulted in the mass spec utility in biomarker standardization efforts.
The capability to perform mass spectrometry testing makes ARDL a more versatile laboratory and offers testing options for trials and studies that can be performed in one laboratory, as opposed to multiple labs sharing samples. “This helps studies streamline their sample workflows, potentially increasing efficiency in the study and reducing errors associated with sample handling,” Seegmiller said.
The success of ARDL resides in the quality of the laboratory testing results. The Mass Spectrometer Center will enable principal investigators and staff to develop improved reference measurement procedures expeditiously. “Our goal is to accommodate various projects in epidemiology, clinical medicine, and public health,” Seegmiller said. “We collaborate with other investigators to devise testing options to aid in answering specific scientific questions that ultimately furthers knowledge in disease states, is translated into clinical guidelines, and impacts patient care,” he added.
ARDL faculty are enthusiastic about the center and excited that the department has invested in it, he said.
ARDL Research Publications
Danni Li, Angela Radulescu, Rupendra T. Shrestha, Matthew Root, Amy B. Karger, Anthony A. Killeen, James S. Hodges, Shu-Ling Fan, Angela Ferguson, Uttam Garg, Lori J. Sokoll, Lynn A. Burmeister. Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA 2017.;318(12):1150-1160.doi:10.1001/jama.2017.13705. https://goo.gl/yeqStZ
Whelton SP, Meeusen JW, Donato LJ, Jaffe AS, Saenger A, Sokoll LJ, Blumenthal RS, Jones SR, Martin SS. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. J Clin Lipidol. 2017 Jul - Aug;11(4):1065-1072. doi: 10.1016/j.jacl.2017.05.005. Epub 2017 Jun 1.
Dan R. Berlowitz, M.D., M.P.H., et al. for the SPRINT Research Group.* Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med 2017; 377:733-744, August 24, 2017. DOI: 10.1056/NEJMoa1611179
Steffen BT, Bielinski SJ, Decker PA, Berardi C, Larson NB, Pankow JS, Michos ED, Hanson NQ, Herrington DM, Tsai MY. Low high-density lipoprotein cholesterol and particle concentrations are associated with greater levels of endothelial activation markers in Multi-Ethnic Study of Atherosclerosis participants. J Clin Lipidol. 2017 Jun 13. pii: S1933-2874(17)30347-1. doi: 10.1016/j.jacl.2017.05.018. [Epub ahead of print]
Bielinski SJ, Berardi C, Decker PA, Larson NB, Bell EJ, Pankow JS, Sale MM, Tang W, Hanson NQ, Wassel CL, de Andrade M, Budoff MJ, Polak JF, Sicotte H, Tsai MY. Hepatocyte growth factor demonstrates racial heterogeneity as a biomarker for coronary heart disease. Heart. 2017 Jun 1. pii: heartjnl-2016-310450. doi: 10.1136/heartjnl-2016-310450. [Epub ahead of print]